Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Aileron Therapeutics Inc

ALRN
2,11
0,00 (0,00%)
21 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/1/202522:06EDGAR2Form 8-K - Current report
10/1/202517:30PRNUSAileron Therapeutics Announces Rebranding to Rein..
09/12/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202422:15PRNUSAileron Therapeutics Reports Third Quarter 2024 Financial..
14/11/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202413:00PRNUSAileron Therapeutics Announces Positive Topline Data from..
31/10/202412:30PRNUSAileron Therapeutics and Advancium Health Network Announce..
12/10/202415:00PRNUSAileron Therapeutics to Present Previously Announced Data..
23/9/202413:30PRNUSAileron Therapeutics Completes Enrollment in Cohort 2 of the..
22/8/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202422:17EDGAR2Form 8-K - Current report
19/8/202422:05PRNUSAileron Therapeutics to Present at the 8th Annual IPF Summit
15/8/202400:05PRNUSAileron Therapeutics Reports Second Quarter 2024 Financial..
14/8/202423:23EDGAR2Form 8-K - Current report
14/8/202423:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/7/202414:00PRNUSAileron Therapeutics to Present at the Canaccord Genuity..
26/7/202422:36EDGAR2Form 8-K - Current report
26/7/202422:33EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/7/202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/7/202414:41EDGAR2Form ARS - Annual Report to Security Holders
09/7/202414:36EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/7/202414:30EDGAR2Form DEF 14A - Other definitive proxy statements
01/7/202414:00PRNUSAileron Therapeutics to be Included in the Russell Microcap®..
05/6/202412:58EDGAR2Form 8-K - Current report
16/5/202423:19EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/5/202423:01EDGAR2Form 8-K - Current report
15/5/202423:16EDGAR2Form 8-K - Current report
15/5/202423:13GLOBEAileron Therapeutics Reports First Quarter 2024 Financial..
15/5/202423:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202422:05GLOBEAileron Therapeutics to Present at Two Upcoming Investor..
03/5/202422:05GLOBEAileron Therapeutics Announces Closing of Underwritten..
01/5/202414:45GLOBEAileron Therapeutics Announces Pricing of Underwritten..
01/5/202414:30GLOBEAileron Therapeutics Announces Positive Data from Cohort 1..
15/4/202423:20GLOBEAileron Therapeutics Reports Fourth Quarter and Full Year..
12/3/202413:00GLOBEAileron Therapeutics Announces CEO Transition
06/3/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202413:01EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 2,11

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network